Recommended dosage of ensidipine for the treatment of AML
Ensidipine, as an innovative drug targeting IDH2 gene mutation acute myeloid leukemia (AML), its dosage is not static. The actual dosage needs to be determined based on the patient's specific condition and the doctor's guidance. Under normal circumstances, doctors recommend that the daily dosage of ensidipine is 100mg, and it should be taken orally once a day.
Before initiating ensidipine treatment, doctors will consider the patient's disease progression, overall health, and whether the patient is taking other medications. This evaluation typically includes a medical history, physical examination, laboratory testing (such as liver and kidney function tests), and an electrocardiogram to ensure that the patient can safely receive ensidipine.

Based on the evaluation results, the doctor will set an appropriate dosage of ensidipine and make necessary adjustments during the treatment process based on patient feedback and drug side effects. Generally speaking, the recommended daily dosage is 100mg once a day, preferably at the same time every day to maintain a stable level of the drug in the body.
For certain patient groups, such as the elderly or those with hepatic and renal impairment, the dosage may need to be adjusted. In addition, if a patient experiences adverse drug reactions or drug-drug interactions, doctors may also adjust the dosage of medication or suspend treatment if necessary.
During the use of ensidipine, patients should strictly abide by the doctor's medication instructions and are not allowed to change the dosage or method of administration without authorization. At the same time, patients should receive regular examinations and follow-up visits from their doctors. Once any discomfort or abnormal reaction occurs, they should report to the doctor immediately so that the treatment plan can be adjusted in a timely manner. By using ensidipine scientifically and rationally, patients are expected to obtain the best therapeutic effects and thereby improve their quality of life.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)